This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
EMD Millipore
other brands :
Oncogene Research Products, Calbiochem, Novagen, Merck, Upstate Biotechnology, Chemicon, LINCO, Novabiochem, Guava
product type :
antibody
product name :
ARNT1/HIF-1β Antibody, clone 4G9
catalog :
05-704
quantity :
200 µg
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
reactivity :
human, mouse
application :
western blot, immunocytochemistry, immunoprecipitation, chromatin immunoprecipitation
citations: 1
Published Application/Species/Sample/Dilution | Reference |
---|---|
| Schnekenburger M, Talaska G, Puga A. Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation. Mol Cell Biol. 2007;27:7089-101 pubmed
|
product information
Catalog Number :
05-704
Subcategory :
Epigenetics & Nuclear Function
Product Name :
Anti-ARNT1/HIF-1β Antibody, clone 4G9
Product Type :
Antibodies
Clonality :
Monoclonal Antibody
Gene ID :
P27540
Host Name :
Mouse
Antigen :
ARNT1/HIF-1β
Conjugate :
Purified
Isotype :
IgG
Product Description :
Anti-ARNT1/HIF-1β Antibody, clone 4G9
Cross Reactivity :
Human;Mouse
Immunogen :
Protein A fusion protein corresponding to residues 399-777 of human aryl hydrocarbon receptor nuclear translocator (ARNT)
Specificity :
ARNT
Package Size :
200 µg
Uses :
Immunoprecipitation;Western Blotting;Immunocytochemistry
Storage :
2 years at -20°C
company information
EMD Millipore
290 Concord Road
Billerica, Massachusetts 01821
Billerica, Massachusetts 01821
bioscienceshelp@emdchemical.com
https://www.emdmillipore.com888-854-3417
headquarters: United States
EMD Millipore is the Life Science division of Merck KGaA of Darmstadt, Germany
Hundreds of New Antibodies in the areas of:
View all the new antibodies at www.emdmillipore.com.
Hundreds of New Antibodies in the areas of:
|
|
questions and comments